Live News EQUITY FLASH L impact Oct 26, 2026, 11:05 AM UTC Fate Therapeutics’ FT819 Shows Renal Response in Two Lupus Nephritis Patients Two patients showed a renal response at six months in the Phase 1 trial. FATE SquawkNews Desk